ANTIBODY FORMULATIONS

PROBLEM TO BE SOLVED: To provide a formulation that retards degradation of an antibody product in the formulation.SOLUTION: The present invention provides antibody formulations, including monoclonal antibodies formulated in a histidine-acetate buffer, and a formulation comprising an antibody that bi...

Full description

Saved in:
Bibliographic Details
Main Authors ANDYA JAMES D, LIU JUN, SHEN YE, GWEE SHIANG C
Format Patent
LanguageEnglish
Published 04.09.2014
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:PROBLEM TO BE SOLVED: To provide a formulation that retards degradation of an antibody product in the formulation.SOLUTION: The present invention provides antibody formulations, including monoclonal antibodies formulated in a histidine-acetate buffer, and a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).
Bibliography:Application Number: JP20140097390